mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

Targeting the PI3K pathway in cancer: are we making headway?

(2018) Filip Janku et al.   Nature Reviews Clinical Oncology

Clinical implications of PTEN loss in prostate cancer

(2018) Tamara Jamaspishvili et al.   Nature Reviews Urology

The evolution of bladder cancer genomics: What have we learned and how can we use it?

(2018) François Audenet et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression

(2018) Ellie Rad et al.   Cancers

mTOR Pathways in Cancer and Autophagy

(2018) Mathieu Paquette et al.   Cancers

mTOR Cross-Talk in Cancer and Potential for Combination Therapy

(2018) Fabiana Conciatori et al.   Cancers

mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression

(2018) Mio Harachi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

(2017) Marko Babjuk et al.   EUROPEAN UROLOGY

Clinical development of mTor inhibitors for renal cancer

(2017) Michele Ghidini et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges

(2017) José Luis González-Larriba et al.   Expert Review of Anticancer Therapy

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

(2017) Afsane Bahrami et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress

(2017) Afsane Bahrami et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

A Review of mTOR Pathway Inhibitors in Gynecologic Cancer

(2017) Andréia Cristina de Melo et al.   Oxidative Medicine and Cellular Longevity

Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity

(2017) Seraina Faes et al.   Oxidative Medicine and Cellular Longevity

Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities

(2017) Claudio Pulito et al.   Cell Discovery

The PI3K/AKT Pathway as a Target for Cancer Treatment

(2016) Ingrid A. Mayer et al.   Annual Review of Medicine

Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers

(2016) M. Morrison Joly et al.   CANCER RESEARCH

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

(2016) D. J. Kwiatkowski et al.   CLINICAL CANCER RESEARCH

Targeting the mTOR Pathway in Leukemia

(2016) Shira Dinner et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt

(2016) Jinfang Zhang et al.   MOLECULAR CELL

mTORC1 and mTORC2 in cancer and the tumor microenvironment

(2016) L C Kim et al.   ONCOGENE

mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review)

(2016) Kai Hu et al.   ONCOLOGY REPORTS

The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines

(2016) Ismael Riquelme et al.   PATHOLOGY & ONCOLOGY RESEARCH

mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle

(2016) I. Ben-Sahra et al.   SCIENCE

mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review

(2016) Cara M. Statz et al.   Targeted Oncology

mTOR inhibitors in urinary bladder cancer

(2016) R. Pinto-Leite et al.   TUMOR BIOLOGY

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

(2016) Xiaoman Li et al.   Oncotarget

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC

(2016) Joseph D. Coppock et al.   Oncotarget

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma

(2015) E. Massarelli et al.   ANNALS OF ONCOLOGY

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer

(2015) E. Deutsch et al.   ANNALS OF ONCOLOGY

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

(2015) Johanna C. Bendell et al.   CANCER

Emerging therapeutic targets in bladder cancer

(2015) Benedito A. Carneiro et al.   CANCER TREATMENT REVIEWS

The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1

(2015) Wilhelm Palm et al.   CELL

Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer

(2015) Milton Seiler et al.   Clinical Breast Cancer

Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384

(2015) A. J. Leiker et al.   CLINICAL CANCER RESEARCH

Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma

(2015) V. Dimitrova et al.   CURRENT MOLECULAR MEDICINE

PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel

(2015) Katharina Pfisterer et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers

(2015) Sally Temraz et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The role for autophagy in cancer

(2015) Eileen White   JOURNAL OF CLINICAL INVESTIGATION

mTOR: a pharmacologic target for autophagy regulation

(2015) Young Chul Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

(2015) Sara A Hurvitz et al.   LANCET ONCOLOGY

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

(2015) S. M. Guichard et al.   MOLECULAR CANCER THERAPEUTICS

Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP

(2015) S J H Ricoult et al.   ONCOGENE

Targeting the genetic alterations of the PI3K–AKT–mTOR pathway: Its potential use in the treatment of bladder cancers

(2015) Nadine Houédé et al.   PHARMACOLOGY & THERAPEUTICS

Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1

(2015) S. Wang et al.   SCIENCE

Sestrin2 is a leucine sensor for the mTORC1 pathway

(2015) R. L. Wolfson et al.   SCIENCE

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

(2015) H. Cheng et al.   Cancer Discovery

PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex

(2015) P. Liu et al.   Cancer Discovery

A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation

(2015) Guang Yang et al.   Cell Reports

PTEN: Multiple Functions in Human Malignant Tumors

(2015) Michele Milella et al.   Frontiers in Oncology

The Prognostic Role of mTOR and P-mTOR for Survival in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2015) Lei Li et al.   PLoS One

PTEN Deficiency Contributes to the Development and Progression of Head and Neck Cancer

(2015) Cristiane H Squarize et al.   NEOPLASIA

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

(2014) M. Piccart et al.   ANNALS OF ONCOLOGY

PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway

(2014) Xiaofang Xing et al.   ANTI-CANCER DRUGS

mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms

(2014) Kathleen A. Wilson-Edell et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma

(2014) James S. Blachly et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma

(2014) Caleb F. Davis et al.   CANCER CELL

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

(2014) Pasquale Cirone et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

(2014) Tanguy Y. Seiwert et al.   CLINICAL CANCER RESEARCH

Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors

(2014) Jennifer Chan et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

HER2 Expression and PI3K-Akt Pathway Alterations in Gastric Cancer

(2014) Yasutaka Sukawa et al.   DIGESTION

A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option

(2014) Konrad Klinghammer et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

(2014) Carolyn D. Britten et al.   INVESTIGATIONAL NEW DRUGS

Prognostic implication of TSC1 and mTOR expression in gastric carcinoma

(2014) Sun-ju Byeon et al.   JOURNAL OF SURGICAL ONCOLOGY

Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis

(2014) Shigeki Umemura et al.   Journal of Thoracic Oncology

A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

(2014) T. Mazumdar et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Making new contacts: the mTOR network in metabolism and signalling crosstalk

(2014) Mitsugu Shimobayashi et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Autophagy, p53, and Pancreatic Cancer

(2014) Christine A. Iacobuzio-Donahue et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients

(2014) JULIETA AFONSO et al.   Oncology Letters

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

(2014) B. C. Grabiner et al.   Cancer Discovery

Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma

(2013) Karen-Lise G. Spindler et al.   ACTA ONCOLOGICA

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer

(2013) B. Besse et al.   ANNALS OF ONCOLOGY

Phase II study of everolimus in metastatic urothelial cancer

(2013) Matthew I. Milowsky et al.   BJU INTERNATIONAL

A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer

(2013) Matthew G. Fury et al.   CANCER

Novel Targeting of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin in Renal Cell Carcinoma

(2013) Daniel Cho   CANCER JOURNAL

Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2

(2013) Sean J. Humphrey et al.   Cell Metabolism

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

(2013) K. Ng et al.   CLINICAL CANCER RESEARCH

Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

(2013) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma

(2013) M.N. Fishman et al.   EUROPEAN JOURNAL OF CANCER

Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)

(2013) Arnoud J. Templeton et al.   EUROPEAN UROLOGY

Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation

(2013) Mei-Ling Chong et al.   INTERNATIONAL JOURNAL OF CANCER

PI3K/AKT pathway activation in bladder carcinogenesis

(2013) Julien Calderaro et al.   INTERNATIONAL JOURNAL OF CANCER

A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer

(2013) Matthew G. Fury et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology

(2013) Venus Thomanetz et al.   JOURNAL OF CELL BIOLOGY

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

(2013) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

(2013) Wouter W. Mellema et al.   Journal of Thoracic Oncology

Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2013) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Genetic variations of mTORC1 genes and risk of gastric cancer in an eastern chinese population

(2013) Jing He et al.   MOLECULAR CARCINOGENESIS

p53 status determines the role of autophagy in pancreatic tumour development

(2013) Mathias T. Rosenfeldt et al.   NATURE

Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis

(2013) Pengda Liu et al.   NATURE CELL BIOLOGY

Signals from the lysosome: a control centre for cellular clearance and energy metabolism

(2013) Carmine Settembre et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer

(2013) B. M. Wolpin et al.   ONCOLOGIST

Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer

(2013) U. WAZIR et al.   ONCOLOGY REPORTS

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

(2013) Julie E. Bauman et al.   ORAL ONCOLOGY

Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer

(2013) Erica L. Bradshaw-Pierce et al.   PLoS One

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy

(2013) M. Weiler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1

(2013) I. Ben-Sahra et al.   SCIENCE

The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro

(2013) Marie N. Becker et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance

(2013) L Chang et al.   Cell Death & Disease

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

(2013) S. J. Klempner et al.   Cancer Discovery

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors

(2013) Matthias Lechner et al.   Genome Medicine

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

(2012) E. Seront et al.   ANNALS OF ONCOLOGY

Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer

(2012) Mari Nakabayashi et al.   BJU INTERNATIONAL

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells

(2012) Benjamin Blaser et al.   BMC CANCER

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

(2012) D H Yoon et al.   BRITISH JOURNAL OF CANCER

A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)

(2012) Matthew G. Fury et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA

(2012) Pat Gulhati et al.   CARCINOGENESIS

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway

(2012) Jung Min Han et al.   CELL

mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors

(2012) Yanjie Zhang et al.   CELL CYCLE

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2012) F. Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas

(2012) A. A. Molinolo et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study

(2012) Thanyanan Reungwetwattana et al.   Journal of Thoracic Oncology

Leucyl-tRNA Synthetase Controls TORC1 via the EGO Complex

(2012) Grégory Bonfils et al.   MOLECULAR CELL

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12

(2012) Xiaoqing Gan et al.   NATURE CELL BIOLOGY

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study

(2012) D. Castellano et al.   ONCOLOGIST

PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies

(2012) Lise Willems et al.   Current Oncology Reports

Role of Phosphatidylinositol-3-Kinase Pathway in Head and Neck Squamous Cell Carcinoma

(2012) Li Du et al.   Journal of Oncology

mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors

(2011) S. Walsh et al.   BREAST

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

(2011) Brett S. Carver et al.   CANCER CELL

PTEN Level in Tumor Suppression: How Much Is Too Little?

(2011) A. Carracedo et al.   CANCER RESEARCH

Decreased Lymphangiogenesis and Lymph Node Metastasis by mTOR Inhibition in Head and Neck Cancer

(2011) V. Patel et al.   CANCER RESEARCH

Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells

(2011) Toshiaki Ohara et al.   CANCER SCIENCE

mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway

(2011) Timothy R. Peterson et al.   CELL

Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

(2011) E. Chiong et al.   CLINICAL CANCER RESEARCH

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

(2011) Yan-Jie Zhang et al.   DRUG DISCOVERY TODAY

Targeting PI3K Signaling as a Therapeutic Approach for Colorectal Cancer

(2011) Jing Zhang et al.   GASTROENTEROLOGY

Activating mutations of TOR (target of rapamycin)

(2011) Molly Hardt et al.   GENES TO CELLS

Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder

(2011) Chih-Hao Sun et al.   HISTOPATHOLOGY

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

(2011) R. Watanabe et al.   JOURNAL OF NUCLEAR MEDICINE

Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma

(2011) B. Kucejova et al.   MOLECULAR CANCER RESEARCH

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

(2011) J. J. Wallin et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

(2011) S. V. Bhagwat et al.   MOLECULAR CANCER THERAPEUTICS

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer

(2011) J. Baselga   ONCOLOGIST

A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1

(2011) Gottfrid Sjödahl et al.   PLoS One

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer

(2011) Jatin Roper et al.   PLoS One

Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers

(2011) L. G. T. Morris et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling

(2011) Y. Yu et al.   SCIENCE

The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling

(2011) P. P. Hsu et al.   SCIENCE

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

(2011) Y. Jiao et al.   SCIENCE

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

In vivo and in vitro effects of RAD001 on bladder cancer

(2011) Carmen Vasconcelos-Nóbrega et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

PI3K/AKT/mTOR Pathway in Angiogenesis

(2011) Jayashree Karar et al.   Frontiers in Molecular Neuroscience

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

(2010) A H M Reid et al.   BRITISH JOURNAL OF CANCER

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo

(2010) Daniel Cejka et al.   CANCER BIOLOGY & THERAPY

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo

(2010) Thorsten Fuereder et al.   CANCER LETTERS

Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids

(2010) Yasemin Sancak et al.   CELL

A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer

(2010) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

The mTOR Pathway: A New Target in Cancer Therapy

(2010) L. Ciuffreda et al.   CURRENT CANCER DRUG TARGETS

EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

(2010) Christian Freudlsperger et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine

(2010) Antonella Perotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer

(2010) Toshihiko Doi et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer

(2010) Sara M. Johnson et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

(2010) Katharine A. Price et al.   Journal of Thoracic Oncology

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

(2010) Katrin Düvel et al.   MOLECULAR CELL

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The genetic basis of kidney cancer: a metabolic disease

(2010) W. Marston Linehan et al.   Nature Reviews Urology

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

(2010) T Sato et al.   ONCOGENE

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

(2010) R. J. O. Dowling et al.   SCIENCE

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

(2009) J.-C. Soria et al.   ANNALS OF ONCOLOGY

Status of PI3K inhibition and biomarker development in cancer therapeutics

(2009) B. Markman et al.   ANNALS OF ONCOLOGY

mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer

(2009) Yan-Jie Zhang et al.   ANNALS OF SURGICAL ONCOLOGY

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

(2009) Robert J. Amato et al.   CANCER

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer

(2009) C. M. Seager et al.   Cancer Prevention Research

Signaling Events Downstream of Mammalian Target of Rapamycin Complex 2 Are Attenuated in Cells and Tumors Deficient for the Tuberous Sclerosis Complex Tumor Suppressors

(2009) J. Huang et al.   CANCER RESEARCH

eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival

(2009) J. R. Graff et al.   CANCER RESEARCH

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer

(2009) F. M. Platt et al.   CLINICAL CANCER RESEARCH

Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer

(2009) G. Yu et al.   CLINICAL CANCER RESEARCH

The Double-Edged Sword of Autophagy Modulation in Cancer

(2009) E. White et al.   CLINICAL CANCER RESEARCH

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

(2009) Todd Morgan et al.   CURRENT CANCER DRUG TARGETS

Inactivation of p53 and Pten promotes invasive bladder cancer

(2009) A. M. Puzio-Kuter et al.   GENES & DEVELOPMENT

The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray

(2009) Li Xiao et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy

(2009) Nao Hosokawa et al.   MOLECULAR BIOLOGY OF THE CELL

ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery

(2009) Chang Hwa Jung et al.   MOLECULAR BIOLOGY OF THE CELL

Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma

(2009) O. Ekshyyan et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The nuts and bolts of AGC protein kinases

(2009) Laura R. Pearce et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Molecular Basis of Colorectal Cancer

(2009) Sanford D. Markowitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis

(2009) C. Nardella et al.   Science Signaling

A Retroinhibition Approach Reveals a Tumor Cell-Autonomous Response to Rapamycin in Head and Neck Cancer

(2008) P. Amornphimoltham et al.   CANCER RESEARCH

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth

(2008) Thomas Porstmann et al.   Cell Metabolism

Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation

(2008) Audrey Carrière et al.   CURRENT BIOLOGY

Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2

(2008) Alfredo Toschi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

(2008) Carolyn Waugh Kinkade et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.

(2008) Jorge A. Garcia et al.   MOLECULAR CANCER THERAPEUTICS

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

(2008) Dana M. Gwinn et al.   MOLECULAR CELL

Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells

(2008) Ira Skvortsova et al.   PROTEOMICS

The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1

(2008) Y. Sancak et al.   SCIENCE